Västra Hamnen Market Focus: Xintela: Focus on study results and financing

• Final study results support XSTEM’s disease-modifying potential in OA
• Rights issue of MSEK 72.8 announced at SEK 0.26 per share
• Q&A with CEO Evy Lundgren Åkerlund on the new Targinta collaboration

Xintela released its Q3 report on November 4 instead of the 21^st as originally scheduled. The company delivered figures much in line with our expectations. A takeaway was a negative operating cash flow of 6.7 MSEK and a cash balance of MSEK 3.4. The financial situation was addressed a few days later when Xintela announced a preferential rights issue of MSEK 72.8.

We will await the outcome of the financing round before updating our forecast and revising the fair value. The full report is available here.